PMID- 15013542
OWN - NLM
STAT- MEDLINE
DCOM- 20040510
LR  - 20221207
IS  - 0266-4356 (Print)
IS  - 0266-4356 (Linking)
VI  - 42
IP  - 2
DP  - 2004 Apr
TI  - Anti-TGFbeta1 antibody for modulation of expression of endogenous transforming 
      growth factor beta 1 to prevent fibrosis after plastic surgery in rats.
PG  - 112-9
AB  - The cytokine transforming growth factor beta 1 (TGFbeta1) substantially 
      influences synthesis of extracellular matrix, fibrosis, and neoangiogenesis 
      during wound healing in a dose dependent manner. We carried out experiments in 
      rats to measure the degree of reduction of disorders of wound healing and 
      fibrosis produced by inhibition of endogenous TGFbeta1 by polyclonal antibodies 
      (poAB). A free myocutaneous gracilis flap was transplanted from the groin to the 
      neck region in 30 Wistar rats (300-450 g body weight). In 15 animals 
      intraoperatively and daily from days 3 to 7 postoperatively, 1 microg 
      anti-TGFbeta1 poAB in 500 microl of phosphate buffered saline (PBS) were injected 
      into the neck region. Fifteen animals served as controls. On postoperative days 
      3, 4, 5, 7, 14, and 28 the expression of endogenous TGFbeta1 in cytoplasm was 
      analysed by immunohistochemistry (ABC-POX; AEC), in situ hybridisation of 
      TGFbeta1-mRNA, and Sirus Red staining of collagen matrix; it was quantified using 
      labelling indices. Neutralisation of the TGFbeta1 activity by specific poAB 
      resulted in inhibition of the cytoplasmatic expression compared with untreated 
      animals. In the transition area between grafted tissue and graft bed, a 
      significant reduction of TGFbeta1 expression (mean (S.D.) 34.7 (6.5)) was found 
      from day 5 in the group treated with anti-TGFbeta1 poAB compared with the control 
      group (mean (S.D.) 48.1 (6.6)) (P <0.03). Up to day 14 the endogenous expression 
      of TGFbeta1 (mean (S.D.) 30.0 (2.8)) was reduced after the application of 
      TGFbeta1 poAB compared with the control group (mean (S.D.) 44.0 (12.3)). Sirus 
      Red staining indicated a more complex packed structure and generally more 
      prominent collagen types I-IV fibres in untreated animals than in animals that 
      were given anti-TGFbeta1 poAB. Expression of TGFbeta-mRNA by in situ 
      hybridisation was reduced in fibroblasts in animals that were given anti-TGFbeta1 
      poAB. The results indicate that anti-TGFbeta1 might improve the healing of free 
      flaps in the graft beds of patients who are prone to excessive fibrosis.
FAU - Schultze-Mosgau, Stefan
AU  - Schultze-Mosgau S
AD  - Department of Oral and Maxillofacial Surgery, University of Erlangen-Nuremberg, 
      Glueckstrasse 11, Erlangen 91054, Germany. 
      stefan.schultze-mosgau@mkg.imed.uni-erlangen.de
FAU - Wehrhan, Falk
AU  - Wehrhan F
FAU - Rodel, Franz
AU  - Rodel F
FAU - Amann, Kerstin
AU  - Amann K
FAU - Radespiel-Troger, Martin
AU  - Radespiel-Troger M
FAU - Kopp, Juergen
AU  - Kopp J
FAU - Grabenbauer, Gerhard
AU  - Grabenbauer G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Scotland
TA  - Br J Oral Maxillofac Surg
JT  - The British journal of oral & maxillofacial surgery
JID - 8405235
RN  - 0 (Antibodies)
RN  - 0 (Tgfb1 protein, rat)
RN  - 0 (Transforming Growth Factor beta)
RN  - 0 (Transforming Growth Factor beta1)
SB  - IM
MH  - Anastomosis, Surgical
MH  - Animals
MH  - Antibodies/pharmacology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Extracellular Matrix/metabolism
MH  - Fibrosis/etiology/*prevention & control
MH  - Immunohistochemistry
MH  - In Situ Hybridization
MH  - Male
MH  - Muscle, Skeletal/blood supply/*transplantation
MH  - Neck/surgery
MH  - Rats
MH  - Rats, Wistar
MH  - Plastic Surgery Procedures/*adverse effects
MH  - Skin Transplantation/*physiology
MH  - Surgical Flaps/blood supply/*immunology
MH  - Transforming Growth Factor beta/*antagonists & 
      inhibitors/*biosynthesis/physiology
MH  - Transforming Growth Factor beta1
MH  - Wound Healing/physiology
EDAT- 2004/03/12 05:00
MHDA- 2004/05/11 05:00
CRDT- 2004/03/12 05:00
PHST- 2003/11/26 00:00 [accepted]
PHST- 2004/03/12 05:00 [pubmed]
PHST- 2004/05/11 05:00 [medline]
PHST- 2004/03/12 05:00 [entrez]
AID - S0266435603002572 [pii]
AID - 10.1016/S0266-4356(03)00257-2 [doi]
PST - ppublish
SO  - Br J Oral Maxillofac Surg. 2004 Apr;42(2):112-9. doi: 
      10.1016/S0266-4356(03)00257-2.